Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | HPGD | P15428 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.45 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.44 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.42 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18136607 | 0.87 | HPGD (0.43) | ALDH1A1HPGDMEN1KMT2AGAA | |
| SCHEMBL18211621 | 0.86 | ALDH1A1 (0.43) | ALDH1A1HPGDMEN1KMT2AGAA | |
| SCHEMBL18136720 | 0.81 | USP30 (0.42) | ALDH1A1HPGDMEN1KMT2AGAA | |
| SCHEMBL18136608 | 0.78 | DRD2 (0.40) | ALDH1A1HPGDMEN1KMT2AGAA | |
| SCHEMBL17678351 | 0.78 | GAA (0.47) | ALDH1A1HPGDMEN1KMT2AGAA | |
| SCHEMBL18136684 | 0.78 | GAA (0.50) | ALDH1A1HPGDMEN1KMT2AGAA | |
| SCHEMBL18136617 | 0.77 | TSHR (0.41) | ALDH1A1HPGDMEN1KMT2AGAA | |
| SCHEMBL25420861 | 0.77 | HCAR1 (0.55) | ALDH1A1HPGDMEN1KMT2AGAA | |
| SCHEMBL18136723 | 0.76 | GAA (0.52) | ALDH1A1HPGDMEN1KMT2AGAA | |
| SCHEMBL18130860 | 0.75 | MAPK1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160326162-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2016-11-10 | — | — | US | disclosed |
| WO-2016164641-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2016-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326162-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K11, MAP4K2, PLK1 | ALDH1A1 3767/4885HPGD 2065/4885MEN1 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.